Aptevo Therapeutics Inc.
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 71.00K | 71.00K | 71.00K | 71.00K | 242.00K |
| Gross Profit | -71.00K | -71.00K | -71.00K | -71.00K | -242.00K |
| SG&A Expenses | 11.77M | 11.81M | 10.36M | 9.84M | 10.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -345.00K | -- | -- | -- | -- |
| Total Operating Expenses | 31.96M | 26.70M | 24.30M | 24.10M | 24.60M |
| Operating Income | -31.96M | -26.70M | -24.30M | -24.10M | -24.60M |
| Income Before Tax | -25.97M | -26.47M | -24.03M | -23.70M | -24.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.97 | -26.47 | -24.03 | -23.70 | -24.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.97M | -26.47M | -24.03M | -23.70M | -24.13M |
| EBIT | -31.96M | -26.70M | -24.30M | -24.10M | -24.60M |
| EBITDA | -31.64M | -26.47M | -24.04M | -23.79M | -24.25M |
| EPS Basic | -202.23 | -191.42 | -151.29 | -- | -- |
| Normalized Basic EPS | -119.36 | -115.53 | -94.55 | -- | -- |
| EPS Diluted | -202.23 | -191.42 | -151.29 | -- | -- |
| Normalized Diluted EPS | -119.36 | -115.53 | -94.55 | -- | -- |
| Average Basic Shares Outstanding | 1.21M | 265.90K | 41.00K | -- | -- |
| Average Diluted Shares Outstanding | 1.21M | 265.90K | 41.00K | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |